Detalles de la búsqueda
1.
An exploratory analysis of the cost-effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model.
Diabet Med
; 41(5): e15303, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38470100
2.
Cost-effectiveness analysis of once-daily insulin glargine 300 U/mL versus insulin degludec 100 U/mL using the BRAVO diabetes model.
Diabet Med
; 40(9): e15112, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37035994
3.
Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100).
Clin Diabetes
; 41(3): 425-434, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37456096
4.
Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.
Diabetes Obes Metab
; 24(8): 1617-1622, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35491520
5.
Post Hoc Analysis Evaluating the Impact of Antihyperglycemic Background Therapies on Attainment of A1C Targets Without Hypoglycemia in the ACHIEVE Control Pragmatic, Real-Life Study.
Diabetes Spectr
; 34(4): 407-418, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34866875
6.
Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
Diabetes Obes Metab
; 22(11): 1995-2003, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32538550
7.
A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
Diabetes Obes Metab
; 22(11): 2004-2012, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32729217
8.
Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
Diabetes Obes Metab
; 21(8): 1906-1913, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30993855
9.
INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
Endocr Pract
; 24(2): 143-149, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29106816
10.
Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
J Manag Care Spec Pharm
; 28(6): 592-603, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35352995
11.
Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control.
J Diabetes Complications
; 35(4): 107831, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33509703
12.
Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program.
Diabetes Ther
; 9(5): 2143-2153, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30218432
13.
Clinical and Economic Outcomes Associated With the Timing of Initiation of Basal Insulin in Patients With Type 2 Diabetes Mellitus Previously Treated With Oral Antidiabetes Drugs.
Clin Ther
; 38(1): 110-21, 2016 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26681210
14.
Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
J Manag Care Spec Pharm
; 21(12): 1172-81, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26679966
15.
Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes.
Diabetes Technol Ther
; 16(2): 76-83, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24266497
16.
Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
Adv Ther
; 31(5): 539-60, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24831915
17.
Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus.
Diabetes Technol Ther
; 15(3): 230-6, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23336845
18.
Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization.
Endocr Pract
; 18(5): 651-9, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22440990
19.
Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital.
Hosp Pract (1995)
; 40(4): 40-8, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23299035
20.
Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
J Clin Endocrinol Metab
; 97(10): 3504-14, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22851487
Resultados
1 -
20
de 20
1
Próxima >
>>